Welcome to our dedicated page for BridgeBio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on BridgeBio Pharma stock.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) is a pioneering commercial-stage biopharmaceutical company that specializes in the discovery, creation, and delivery of transformative medicines for patients suffering from genetic diseases and cancers with clear genetic drivers. Established in 2015, the company is headquartered in Palo Alto, California. BridgeBio's mission is to address significant unmet medical needs through genetic medicine by leveraging a comprehensive pipeline of development programs that span from early-stage scientific research to late-stage clinical trials.
The company's core focus areas include Mendelian diseases, Genetic Dermatology, Oncology, and Gene Therapy. BridgeBio’s innovative approach involves systematically mapping the genetic disease landscape to identify promising therapeutic assets. Their proprietary platform and management expertise are harnessed to accelerate the development of these early-stage assets into clinically impactful treatments.
BridgeBio’s robust pipeline boasts several notable programs:
- Acoramidis (AG10): Aiming to treat transthyretin amyloid cardiomyopathy (ATTR-CM), this next-generation, orally-administered TTR stabilizer has shown positive results in the Phase 3 ATTRibute-CM trial. The New Drug Application (NDA) for acoramidis has been accepted by the FDA, with a target decision date set for November 29, 2024.
- Infigratinib: Targeting achondroplasia and hypochondroplasia, this FGFR1-3 inhibitor aims to address skeletal dysplasias. The PROPEL 2 Phase 2 trial has demonstrated significant and sustained increases in growth velocity.
- BBP-418: Designed for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), this glycosylation substrate is under Phase 3 trials, with the potential for accelerated approval based on recent interactions with the FDA.
BridgeBio's track record includes successful capital raises, strategic partnerships, and a series of public offerings that have strengthened its financial positioning. The company recently completed a $200 million private financing for its oncology subsidiary, BridgeBio Oncology Therapeutics, to accelerate the development of its precision oncology pipeline.
Key recent developments include:
- The initiation of a comprehensive equity grants program to attract top talent in the biopharmaceutical industry.
- Positive results from multiple clinical trials, including significant improvements in health-related quality of life measures for patients with ATTR-CM treated with acoramidis.
- Ongoing collaborations with global pharmaceutical leaders like Bayer for the commercial development and distribution of key assets in international markets.
BridgeBio remains committed to advancing genetic medicine and delivering groundbreaking therapies to improve patient lives. For more information, visit bridgebio.com and follow them on LinkedIn and Twitter.
News
Rhea-AI Summary
BridgeBio Pharma, Inc. submits NDA for acoramidis to FDA for ATTR-CM treatment, presents positive Phase 3 trial results, secures funding, and reports financial results for Q4 and full year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
-
Rhea-AI Summary
BridgeBio Pharma, Inc. and Kyowa Kirin Co., Ltd announced a partnership for the development and commercialization of infigratinib for achondroplasia, hypochondroplasia, and other skeletal dysplasias in Japan. BridgeBio will receive an upfront payment of USD 100 million and royalties on sales of infigratinib in Japan. Infigratinib is an oral small molecule designed to inhibit FGFR3 and target FGFR3-driven skeletal dysplasias, including achondroplasia and hypochondroplasia. The partnership aims to accelerate the development of infigratinib to provide treatment options for children with achondroplasia, hypochondroplasia, and other skeletal dysplasias in Japan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
-
Rhea-AI Summary
BridgeBio Pharma, Inc. granted 123,838 shares of common stock to 35 new employees as part of their compensation package. The shares will vest over time, subject to continued employment. The awards were made under the company's 2019 Inducement Equity Plan, adopted in November 2019 and subsequently amended in February and December 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
Rhea-AI Summary
BridgeBio Pharma, Inc. announces that the U.S. FDA has accepted the New Drug Application (NDA) for acoramidis, a drug for the treatment of ATTR-CM, with a PDUFA action date of November 29, 2024. The FDA is not planning to hold an advisory committee meeting. The European Medicines Agency has also accepted the Marketing Authorization Application, with additional global regulatory submissions planned. ATTRibute-CM study results showed positive outcomes, including an 81% absolute survival rate, low cardiovascular-related hospitalization frequency, and rapid clinical benefit.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
-
Rhea-AI Summary
BridgeBio Pharma, Inc. (Nasdaq: BBIO) shared positive results from the Japan Phase III trial of acoramidis in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), conducted by Alexion, AstraZeneca Rare Disease. The results showed consistency with the global BridgeBio ATTRibute-CM Phase III trial, with no mortality reported over the 30-month treatment period. Acoramidis was well-tolerated, with no safety signals of potential clinical concern identified. The findings support local regulatory submission in Japan. The data will be presented at a forthcoming medical meeting and submitted to Japan’s health authority for regulatory review. Acoramidis is an investigational, next-generation, oral, highly potent small molecule stabilizer of transthyretin (TTR), designed to achieve maximal stabilization and preserve native TTR.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
-
Rhea-AI Summary
Invitae (NVTA) announces a partnership with BridgeBio Pharma (BBIO) to advance genetics-based drug discovery for rare diseases. The collaboration aims to generate new insights focused on genetic modifiers and the discovery of novel therapeutic targets for rare diseases and other unmet medical needs. Invitae's extensive dataset and analytical capabilities will be combined with BridgeBio's expertise in rare disease research and therapeutic development to support the development of transformative medicines for patients with rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.62%
Tags
Rhea-AI Summary
BridgeBio Pharma, Inc. secures strategic financing of up to $1.25 billion from Blue Owl Capital and CPP Investments to support the anticipated launch of acoramidis, a potential therapy for transthyretin amyloid cardiomyopathy (ATTR-CM). The financing includes $500 million in cash from Blue Owl and CPP Investments, a $450 million credit facility from Blue Owl, and the possibility of an additional $300 million credit facility. The royalty agreement with Blue Owl and CPPIB Credit entails a 5% royalty on future global net sales of acoramidis, capped at 1.9 times the invested capital. The refinancing with Blue Owl extends maturity from 2026 to 2029, providing operational flexibility. The financing positions BridgeBio well to launch acoramidis and accelerate its genetic medicine R&D engine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.76%
Tags
-
Rhea-AI Summary
BridgeBio Pharma, Inc. (BBIO) announced positive results from its Phase 3 ATTRibute-CM study of acoramidis for patients with ATTR-CM, demonstrating a significant treatment effect with a 1.8 Win Ratio and 80.7% survival rate. Acoramidis was well-tolerated, with no safety concerns identified. BridgeBio submitted a New Drug Application to the FDA and plans to submit marketing authorization applications to additional regulatory bodies in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.7%
Tags
-
Rhea-AI Summary
BridgeBio Pharma, a commercial-stage biopharmaceutical company (Nasdaq: BBIO), granted 66,963 shares of restricted stock units to twenty-five new employees. Vesting of shares will occur on February 16, 2025, with subsequent vesting on a quarterly basis, subject to continued employment. The awards were made under the Amended and Restated 2019 Inducement Equity Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
Rhea-AI Summary
BridgeBio Pharma, Inc. (Nasdaq: BBIO) to present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
FAQ
What is the current stock price of BridgeBio Pharma (BBIO)?
The current stock price of BridgeBio Pharma (BBIO) is $26.49 as of December 20, 2024.
What is the market cap of BridgeBio Pharma (BBIO)?
The market cap of BridgeBio Pharma (BBIO) is approximately 5.0B.
What does BridgeBio Pharma, Inc. specialize in?
BridgeBio Pharma specializes in discovering, creating, and delivering transformative medicines for patients suffering from genetic diseases and cancers with clear genetic drivers.
What are the core focus areas of BridgeBio Pharma's pipeline?
The core focus areas include Mendelian diseases, Genetic Dermatology, Oncology, and Gene Therapy.
What are some key programs in BridgeBio's pipeline?
Key programs include acoramidis (AG10) for ATTR-CM, infigratinib for achondroplasia and hypochondroplasia, and BBP-418 for LGMD2I/R9.
What recent financial achievements has BridgeBio Pharma accomplished?
BridgeBio recently completed a $200 million private financing for its oncology subsidiary and has conducted multiple public offerings.
Has BridgeBio Pharma formed any significant partnerships?
Yes, BridgeBio has partnered with global pharmaceutical leaders like Bayer for the commercial development and distribution of key assets.
What recent clinical trial results has BridgeBio Pharma announced?
BridgeBio announced positive results from the Phase 3 ATTRibute-CM trial for acoramidis, showing significant improvements in health-related quality of life for patients with ATTR-CM.
When was BridgeBio Pharma founded?
BridgeBio Pharma was founded in 2015.
Where is BridgeBio Pharma headquartered?
BridgeBio Pharma is headquartered in Palo Alto, California.
What is the therapeutic approach of BridgeBio Pharma?
BridgeBio Pharma applies a systematic mapping of the genetic disease landscape to identify promising therapeutic assets and leverages its proprietary platform to develop these assets into impactful treatments.
How can I learn more about BridgeBio Pharma’s developments?
For more information, visit bridgebio.com and follow BridgeBio on LinkedIn and Twitter.
BridgeBio Pharma, Inc.
Nasdaq:BBIO
BBIO Rankings
BBIO Stock Data
4.98B
149.78M
5.4%
94.16%
9.09%
Biotechnology
Pharmaceutical Preparations
United States of America
PALO ALTO